{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:21:56Z","timestamp":1755220916471,"version":"3.43.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Malignant melanoma originating in the lungs is relatively rare, accounting for only 0.01% of lung tumors, and has a poor prognosis and is prone to distant metastasis. Notably, melanoma is the third most common source of intracranial metastases in adults, after lung and breast cancer. Primary malignant melanoma of the lung with meningeal metastasis is more rare and has a worse prognosis. There is no effective and unified treatment plan in clinical practice, and the main treatment is comprehensive treatment, which mainly includes surgery, radiation therapy, immunotherapy and targeted therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>The patient was a 52-year-old male with no history of smoking. PET-CT showed a mass in the main bronchus of the right lung, consistent with the metabolic changes of malignant melanoma. Combined with pathology, we finally identified the patient as a primary pulmonary malignant melanoma. About two years later, the patient developed meningeal metastases. The patients was mainly treated with radiation therapy combined with immunotherapy, and the overall survival was about 30 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The diagnosis of pulmonary primary malignant melanoma requires a combination of many factors and is easy to be misdiagnosed. At present, there is no specific effective treatment plan, and such patients have a poor prognosis, are prone to distant metastasis, and their survival will be greatly shortened. The survival period of the patient in this case is longer than the average survival period of such patients, and the possibility of benefiting from immunotherapy is higher. Radiotherapy also reduces the discomfort symptoms of the patient to a certain extent, prolongs the survival of the patient, and provides certain ideas for clinical treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1491350","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T05:24:50Z","timestamp":1754630690000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: A long-term survival case of primary malignant melanoma of the lung with meningeal metastasis"],"prefix":"10.3389","volume":"15","author":[{"given":"Ying","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanchun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623316632072","article-title":"UV-induced melanin chemiexcitation: A new mode of melanoma pathogenesis","volume":"44","author":"Brash","year":"2016","journal-title":"Toxicol Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA\u00a0Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"6395","DOI":"10.3390\/ijms22126395","article-title":"Aetiology and pathogenesis of cutaneous melanoma: current concepts and advances","volume":"22","author":"Strashilov","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199710000-00010","article-title":"Primary melanoma of the lung: a clinicopathologic and immunohistochemical study of eight cases","volume":"21","author":"Wilson","year":"1997","journal-title":"Am J Surg Pathol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.3390\/cancers15164088","article-title":"Current treatment of melanoma brain metastases","volume":"15","author":"Nowacka","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2015.03.011","article-title":"Dark sputum: An atypical presentation of primary pulmonary Malignant melanoma","volume":"15","author":"Filippini","year":"2015","journal-title":"Respir Med Case Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.109306","article-title":"Oncologic PET\/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma","volume":"53","author":"Buchbender","year":"2012","journal-title":"J Nucl Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1981.tb01787.x","article-title":"Pathogenesis of generalized melanosis with melanuria and melanoptysis secondary to Malignant melanoma","volume":"5","author":"Eide","year":"1981","journal-title":"Histopathology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11748-009-0454-9","article-title":"Primary Malignant melanoma of the lung with rapid progression","volume":"57","author":"Maeda","year":"2009","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e8772","DOI":"10.1097\/MD.0000000000008772","article-title":"Primary Malignant melanoma of the lung: A case report and literature review","volume":"96","author":"Peng","year":"2017","journal-title":"Med (Baltimore)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12798","article-title":"Primary pulmonary Malignant melanoma: Case report and literature review","volume":"9","author":"Shi","year":"2018","journal-title":"Thorac Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4065\/74.1.62","article-title":"Primary pulmonary melanoma: case report and literature review","volume":"74","author":"Ost","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"B13","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3390\/medicina56110576","article-title":"Primary melanoma of the lung: A systematic review","volume":"56","author":"Paliogiannis","year":"2020","journal-title":"Medicina (Kaunas)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.humpath.2013.02.007","article-title":"Value of melanocytic-associated immunohistochemical markers in the diagnosis of Malignant melanoma: a review and update","volume":"45","author":"Ordonez","year":"2014","journal-title":"Hum Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2020.12.009","article-title":"FNBP1-BRAF fusion in a primary melanoma of the lung","volume":"53","author":"Kervarrec","year":"2021","journal-title":"Pathology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-017-0575-8","article-title":"The role of surgery for melanoma in an era of effective systemic therapy","volume":"19","author":"Raigani","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2019.1640032","article-title":"Current state of melanoma diagnosis and treatment","volume":"20","author":"Davis","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-017-2591-9","article-title":"Metastatic melanoma: prognostic factors and survival in patients with brain metastases","volume":"135","author":"Frinton","year":"2017","journal-title":"J Neurooncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3171\/jns.1998.88.1.0011","article-title":"Demographics, prognosis, and therapy in 702 patients with brain metastases from Malignant melanoma","volume":"88","author":"Sampson","year":"1998","journal-title":"J\u00a0Neurosurg"},{"key":"B20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/exd.14286","article-title":"Melanoma brain metastases: Biological basis and novel therapeutic strategies","volume":"31","author":"Phadke","year":"2022","journal-title":"Exp Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1186\/s12885-023-11286-3","article-title":"Propensity score-matched analysis comparing hippocampus-avoidance whole-brain radiotherapy plus simultaneous integrated boost with hippocampus\u2212avoidance whole-brain radiotherapy alone for multiple brain metastases-a retrospective study in multiple institutions","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2018.06.017","article-title":"Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes","volume":"128","author":"Gabani","year":"2018","journal-title":"Radiother Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13578-019-0349-0","article-title":"Suppressing immunotherapy by organ-specific tumor microenvironments: what is in the brain","volume":"9","author":"Zhang","year":"2019","journal-title":"Cell Biosci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12967-017-1341-2","article-title":"Future perspectives in melanoma research \u201cMelanoma Bridge\u201d, Napoli, November 30th-3rd December 2016","volume":"15","author":"Ascierto","year":"2017","journal-title":"J Transl Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1903827","article-title":"Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review","volume":"18","author":"Tagliaferri","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3922","article-title":"Safety, efficacy, and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial","volume":"26","author":"Tang","year":"2020","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1491350\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T05:24:52Z","timestamp":1754630692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1491350\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":26,"alternative-id":["10.3389\/fonc.2025.1491350"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1491350","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"article-number":"1491350"}}